{"id":13851,"date":"2017-09-22T09:20:07","date_gmt":"2017-09-22T09:20:07","guid":{"rendered":"https:\/\/celonpharma.com\/?p=13851"},"modified":"2018-02-08T09:20:47","modified_gmt":"2018-02-08T09:20:47","slug":"gg-parkiet-about-the-companys-financial-results-and-plans-for-the-coming-months","status":"publish","type":"post","link":"https:\/\/celonpharma.com\/en\/gg-parkiet-about-the-companys-financial-results-and-plans-for-the-coming-months\/","title":{"rendered":"GG Parkiet \u2013 about the company&#8217;s financial results and plans for the coming months"},"content":{"rendered":"<p>A publication dedicated to the company\u2019s financial results in the first half of 2017 and the company\u2019s plans in terms of clinical development of drug candidates.<br \/>\nMaciej Wieczorek, PhD:\u00a0Our generic drugs recorded similar sales rates to last year, which was in line with our expectations.\u00a0Our financial result in the first half of the year was impacted by the lack of one-off (milestone) payments for the concluded agreements on the distribution of Salmex and discontinuation of manufacturing of Asaris for Polfarmex S.A.\u00a0We have very ambitious plans for the development of our new drugs. Three of our innovative projects will begin clinical development this year. Over the next four years, at least 12 projects will reach the clinical development phase. We should receive the first results of the 2a phase which provides information on the efficacy and safety of drugs for 2-3 drugs in the first half of 2019. Then, in line with the previously provided information, we want to sign parenting agreements.<br \/>\nMore information can be found at GG Parkiet (22.09.2017).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A publication dedicated to the company\u2019s financial results in the first half of 2017 and the company\u2019s plans in terms of clinical development of drug candidates. Maciej Wieczorek, PhD:\u00a0Our generic drugs recorded similar sales rates to last year, which was in line with our expectations.\u00a0Our financial result in the first half of the year was<a class=\"excerpt-read-more float-right\" href=\"https:\/\/celonpharma.com\/en\/gg-parkiet-about-the-companys-financial-results-and-plans-for-the-coming-months\/\" title=\"ReadGG Parkiet \u2013 about the company&#8217;s financial results and plans for the coming months\">Read more &raquo;<\/a><\/p>\n","protected":false},"author":11,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[30],"tags":[],"class_list":["post-13851","post","type-post","status-publish","format-standard","hentry","category-general-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>GG Parkiet \u2013 about the company&#039;s financial results and plans for the coming months - Celon Pharma<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/celonpharma.com\/en\/gg-parkiet-about-the-companys-financial-results-and-plans-for-the-coming-months\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GG Parkiet \u2013 about the company&#039;s financial results and plans for the coming months - Celon Pharma\" \/>\n<meta property=\"og:description\" content=\"A publication dedicated to the company\u2019s financial results in the first half of 2017 and the company\u2019s plans in terms of clinical development of drug candidates. Maciej Wieczorek, PhD:\u00a0Our generic drugs recorded similar sales rates to last year, which was in line with our expectations.\u00a0Our financial result in the first half of the year wasRead more &raquo;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/celonpharma.com\/en\/gg-parkiet-about-the-companys-financial-results-and-plans-for-the-coming-months\/\" \/>\n<meta property=\"og:site_name\" content=\"Celon Pharma\" \/>\n<meta property=\"article:published_time\" content=\"2017-09-22T09:20:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2018-02-08T09:20:47+00:00\" \/>\n<meta name=\"author\" content=\"S\u0142awomir Ni\u017cnik\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"S\u0142awomir Ni\u017cnik\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/gg-parkiet-about-the-companys-financial-results-and-plans-for-the-coming-months\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/gg-parkiet-about-the-companys-financial-results-and-plans-for-the-coming-months\\\/\"},\"author\":{\"name\":\"S\u0142awomir Ni\u017cnik\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/44c54386ed112173d6e8bcbeb6425338\"},\"headline\":\"GG Parkiet \u2013 about the company&#8217;s financial results and plans for the coming months\",\"datePublished\":\"2017-09-22T09:20:07+00:00\",\"dateModified\":\"2018-02-08T09:20:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/gg-parkiet-about-the-companys-financial-results-and-plans-for-the-coming-months\\\/\"},\"wordCount\":186,\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/gg-parkiet-about-the-companys-financial-results-and-plans-for-the-coming-months\\\/\",\"url\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/gg-parkiet-about-the-companys-financial-results-and-plans-for-the-coming-months\\\/\",\"name\":\"GG Parkiet \u2013 about the company's financial results and plans for the coming months - Celon Pharma\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#website\"},\"datePublished\":\"2017-09-22T09:20:07+00:00\",\"dateModified\":\"2018-02-08T09:20:47+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/44c54386ed112173d6e8bcbeb6425338\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/gg-parkiet-about-the-companys-financial-results-and-plans-for-the-coming-months\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/celonpharma.com\\\/en\\\/gg-parkiet-about-the-companys-financial-results-and-plans-for-the-coming-months\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/gg-parkiet-about-the-companys-financial-results-and-plans-for-the-coming-months\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GG Parkiet \u2013 about the company&#8217;s financial results and plans for the coming months\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/\",\"name\":\"Celon Pharma\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/44c54386ed112173d6e8bcbeb6425338\",\"name\":\"S\u0142awomir Ni\u017cnik\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GG Parkiet \u2013 about the company's financial results and plans for the coming months - Celon Pharma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/celonpharma.com\/en\/gg-parkiet-about-the-companys-financial-results-and-plans-for-the-coming-months\/","og_locale":"en_US","og_type":"article","og_title":"GG Parkiet \u2013 about the company's financial results and plans for the coming months - Celon Pharma","og_description":"A publication dedicated to the company\u2019s financial results in the first half of 2017 and the company\u2019s plans in terms of clinical development of drug candidates. Maciej Wieczorek, PhD:\u00a0Our generic drugs recorded similar sales rates to last year, which was in line with our expectations.\u00a0Our financial result in the first half of the year wasRead more &raquo;","og_url":"https:\/\/celonpharma.com\/en\/gg-parkiet-about-the-companys-financial-results-and-plans-for-the-coming-months\/","og_site_name":"Celon Pharma","article_published_time":"2017-09-22T09:20:07+00:00","article_modified_time":"2018-02-08T09:20:47+00:00","author":"S\u0142awomir Ni\u017cnik","twitter_card":"summary_large_image","twitter_misc":{"Written by":"S\u0142awomir Ni\u017cnik","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/celonpharma.com\/en\/gg-parkiet-about-the-companys-financial-results-and-plans-for-the-coming-months\/#article","isPartOf":{"@id":"https:\/\/celonpharma.com\/en\/gg-parkiet-about-the-companys-financial-results-and-plans-for-the-coming-months\/"},"author":{"name":"S\u0142awomir Ni\u017cnik","@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/44c54386ed112173d6e8bcbeb6425338"},"headline":"GG Parkiet \u2013 about the company&#8217;s financial results and plans for the coming months","datePublished":"2017-09-22T09:20:07+00:00","dateModified":"2018-02-08T09:20:47+00:00","mainEntityOfPage":{"@id":"https:\/\/celonpharma.com\/en\/gg-parkiet-about-the-companys-financial-results-and-plans-for-the-coming-months\/"},"wordCount":186,"articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/celonpharma.com\/en\/gg-parkiet-about-the-companys-financial-results-and-plans-for-the-coming-months\/","url":"https:\/\/celonpharma.com\/en\/gg-parkiet-about-the-companys-financial-results-and-plans-for-the-coming-months\/","name":"GG Parkiet \u2013 about the company's financial results and plans for the coming months - Celon Pharma","isPartOf":{"@id":"https:\/\/celonpharma.com\/en\/#website"},"datePublished":"2017-09-22T09:20:07+00:00","dateModified":"2018-02-08T09:20:47+00:00","author":{"@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/44c54386ed112173d6e8bcbeb6425338"},"breadcrumb":{"@id":"https:\/\/celonpharma.com\/en\/gg-parkiet-about-the-companys-financial-results-and-plans-for-the-coming-months\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/celonpharma.com\/en\/gg-parkiet-about-the-companys-financial-results-and-plans-for-the-coming-months\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/celonpharma.com\/en\/gg-parkiet-about-the-companys-financial-results-and-plans-for-the-coming-months\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/celonpharma.com\/en\/"},{"@type":"ListItem","position":2,"name":"GG Parkiet \u2013 about the company&#8217;s financial results and plans for the coming months"}]},{"@type":"WebSite","@id":"https:\/\/celonpharma.com\/en\/#website","url":"https:\/\/celonpharma.com\/en\/","name":"Celon Pharma","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/celonpharma.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/44c54386ed112173d6e8bcbeb6425338","name":"S\u0142awomir Ni\u017cnik"}]}},"_links":{"self":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/13851","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/comments?post=13851"}],"version-history":[{"count":1,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/13851\/revisions"}],"predecessor-version":[{"id":13852,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/13851\/revisions\/13852"}],"wp:attachment":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/media?parent=13851"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/categories?post=13851"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/tags?post=13851"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}